Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.77 |
| ▸ | HTR2B | P41595 | 3/20 | 0.77 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.58 |
| ▸ | CTSC | P53634 | 1/20 | 0.57 |
| ▸ | MC4R | P32245 | 2/20 | 0.56 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1789145 | 1.00 | HTR2C (0.77) | HTR2CHTR2BUSP2ALDH1A1HPGD | |
| SCHEMBL7874030 | 1.00 | HTR2C (0.77) | HTR2CHTR2BUSP2ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL7607289 | 0.98 | HTR2C (0.75) | HTR2CHTR2BUSP2ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL18337901 | 0.98 | HTR2C (0.75) | HTR2CHTR2BUSP2ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL4368425 | 0.98 | HTR2C (0.75) | HTR2CHTR2BUSP2ALDH1A1HPGD | |
| SCHEMBL9469301 | 0.95 | HTR2C (0.71) | HTR2CHTR2BUSP2ALDH1A1HPGD | |
| SCHEMBL9469302 | 0.95 | HTR2C (0.71) | HTR2CHTR2BUSP2ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL18337653 | 0.94 | HTR2C (0.70) | HTR2CHTR2BUSP2ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL3267987 | 0.94 | HTR2C (0.70) | HTR2CHTR2BUSP2ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL18337654 | 0.94 | HTR2C (0.70) | HTR2CHTR2BUSP2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110240631-B | Chiral isoindolone cyclopeptide derivative, preparation method and application thereof | 哈尔滨师范大学 | 2023-02-17 | — | — | CN | disclosed |
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
| US-10793582-B2 | Bicyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-10-06 | — | — | US | disclosed |
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-08-01 | — | — | US | disclosed |
| US-8048862-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-8048862-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-20110059047-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| WO-2009142842-A9 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2009142842-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090269305-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090269305-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| EP-1745019-A1 | NOVEL COMPOUNDS OF PROLINE AND MORPHOLINE DERIVATIVES | PFIZER INC. (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CHENG HENGMIAO | 2005-11-24 | — | — | US | disclosed |
| WO-2005108359-A1 | NOVEL COMPOUNDS OF PROLINE AND MORPHOLINE DERIVATIVES | PFIZER INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269305-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | HTR2C 3859/4885HTR2B 4587/4885USP2 2540/4885 |
| US-20110059047-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | HTR2C 3859/4885HTR2B 4587/4885USP2 2540/4885 |
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | KAT2A, KAT7, KAT5 | HTR2C 2785/4885HTR2B 3182/4885USP2 1046/4885 |
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CYP11B1, HSD11B1, CYP11B2 | HTR2C 406/4885HTR2B 609/4885USP2 3806/4885 |
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | HTR2C 208/4885HTR2B 28/4885USP2 2378/4885 |
| US-10793582-B2 | Bicyclic heterocyclic compound | KAT2A, KAT7, KAT5 | HTR2C 2687/4885HTR2B 3104/4885USP2 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.